Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Blood (2025) 146 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2025-3601

Published: 2025

Journal Articles

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Michael Wang, Jonas Paludo, João Samuel de Holanda Farias, Diego Villa, Cecily Forsyth, Ellie John, Menglu Che, Harneet Arora, Craig Delury, Victoria Otero, Yuqin Song

Blood (2025) 146 (Supplement 1): 885.

https://doi.org/10.1182/blood-2025-885

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

Blood (2025) 146 (Supplement 1): 5806.

https://doi.org/10.1182/blood-2025-5806

Published: 2025

Journal Articles

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Adam Suleman, Kim Roos, Yidi Jiang, George Tomlinson, Kathryn Mangoff, Gail Klein, Diego Villa, David Macdonald, Mohammed Aljama, Mona Shafey, Nicholas Forward, Jean-Francois Larouche, Anna Nikonova, Michael Sebag, Irwindeep Sandhu, Rebecca McClure, Heidi Simmons, Monica Gallucci, Neil Berinstein

Blood (2025) 146 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2025-1814

Published: 2025

Journal Articles

Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia

Jonathan Isenberg, Kerry Savage, David Scott, Laurie Sehn, Christopher Venner, Diego Villa, Alina Gerrie

Blood (2025) 146 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2025-1805

Published: 2025

Journal Articles

Real world population-based outcome analysis of small lymphocytic lymphoma (SLL) in British Columbia (BC)

Solomon Abate, Steven Huang, Elysha Vanderveer, Diego Villa, Christopher Venner, David Scott, Kerry Savage, Laurie Sehn, Cynthia Toze, Alina Gerrie

Blood (2025) 146 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2025-2748

Published: 2025

Journal Articles

CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature–expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K. Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Andrew J. Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood (2025) 145 (6): 590–596.

https://doi.org/10.1182/blood.2024025725

Published: 2025

Includes: Supplemental data

Journal Articles

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Phillip Scheinberg, Diego Villa Cle, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jörg Schubert, Kazutaka Sunami, Mustafa Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 1313.

https://doi.org/10.1182/blood-2024-200745

Published: 2024

Journal Articles

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Jiayu Yang, Anna R. Hayden, Diego Villa, Aixiang Jiang, Alina S. Gerrie, Christopher P. Venner, Pedro Farinha, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 574.

https://doi.org/10.1182/blood-2024-198794

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6291.

https://doi.org/10.1182/blood-2024-203317

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Nicolas Champagne, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Graham W. Slack, Pedro Farinha, Jeffrey W Craig, Laura Hilton, Kerry J. Savage, David W. Scott, Laurie H. Sehn

Blood (2024) 144 (Supplement 1): 109.

https://doi.org/10.1182/blood-2024-201819

Published: 2024

Journal Articles

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Jiayu Yang, Diego Villa, Alina S. Gerrie, Petter Tonseth, Don C. Wilson, Francois Benard, Graham W. Slack, Christopher P. Venner, Andrea C. Lo, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 461.

https://doi.org/10.1182/blood-2024-194858

Published: 2024

Journal Articles

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Jean-Nicolas Champagne, Steven Huang, Rayan Ramadan, Christopher P. Venner, Khaled Ramadan, Laurie H. Sehn, Kerry J. Savage, Diego Villa, David W. Scott, Waleed Alduaij, Cynthia L. Toze, Alina S. Gerrie

Blood (2024) 144 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2024-198028

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Blood (2024) 144 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2024-204328

Published: 2024

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Diego Villa, Jean-Francois Larouche, Matthew C. Cheung, Mary-Margaret Keating, Katherine Zukotynski, Petter Tonseth, Samantha Mayo, Robert Laister, David W. Scott, John Kuruvilla

Blood (2023) 142 (Supplement 1): 3042.

https://doi.org/10.1182/blood-2023-179375

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons

Blood (2023) 142 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2023-186347

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia

Real world population-based outcome analysis of small lymphocytic lymphoma (SLL) in British Columbia (BC)

CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature–expressing DLBCL

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only